MITTEL GEGEN KREBS!!!! Nachstudie Campath zeigt Superwirkung!! - 500 Beiträge pro Seite

[Warren Bluffet]

- eine Langzeit-Nachstudie zu Campath zeigt hevorragende Wirkung in der Bekämpfung von Krebszellen.
- Leben der schwer erkrankten Patienten wird deutlich verlängert
- in USA gesten schon der Tagessieger alle Bio-aktien.
- zudem ist dieses Medikament auch noch vermutlich gegen Multiple Sklerose wirksam.
- 5 weitere Produkte in der Pipeline
- 3 weitere Produkte in vorklinischen Phasen.
- zudem auch noch charttechnisch in der Aufschwungphase



------------------------------------------------

Increased Life Expectancy

BERLIN, May 14 -- Life expectancy for heavily pre-treated B-CLL patients, who were subsequently treated with Campath/MabCampath(alemtuzumab), was shown to double, from 8 to 16 months, in follow-up data from the international phase II pivotal study (CAM211) published this month in "Blood," the Journal of the American Society of Hematology.

Furthermore, for those patients who responded to Campath/MabCampath therapy, the study showed an average life expectancy of 32 months.

"Life expectancy for patients who have been treated with alkylating agents and have failed therapy with Fludara(R) was typically 8 - 12 months and there was no other treatment option available. However, of the 31 patients who responded to Campath (33% of all patients), 19 were alive 21 - 34 months post-treatment. These results mark a significant advance for the treatment of B-CLL," said Dr. Michael J. Keating, Professor of Medicine at University of Texas M. D. Anderson Cancer Center and the study`s lead author, explaining the importance of the study`s results to B-CLL treatment.

Professor Gunter Stock, Schering`s Executive Director for Research and Development added: "We are pleased to see the publication of these important follow-up data from the CAM211 study. The response rate and increased life expectancy bring new hope to this group of heavily pre-treated patients for whom no approved therapeutic options were available to control their cancer. Schering is committed to the treatment of leukemia and we consider Campath a major component of our oncology strategy. Research that will benefit leukemia and lymphoma patients is a priority for Schering. We will continue to investigate new treatments and new indications for Fludara and Campath, as well as for Zevalin(TM), which is expected to receive EU approval in 2002 as the first radioimmunotherapeutic agent for the treatment of non-Hodgkin`s lymphoma (NHL)."

The published study involved 93 heavily pre-treated B-CLL patients at 21 centers worldwide. All study participants had received previous therapy with alkylating agents and were refractory to Fludara (fludarabine phosphate), recognized as the most effective 2nd line treatment for B-CLL patients. Investigators observed clinical benefit and symptom relief in both responders and patients with stable disease (SD).

According to Dr. Peter Hillmen, Consultant Hematologist at Pinderfields General Hospital, Wakefield and Leeds Infirmary, and one of the study`s principal investigators, "Campath`s effect on the bone marrow is extremely important because involvement of the bone marrow with CLL is a major problem in many patients which is extremely difficult to treat and frequently contributes to the patient`s death." Investigators treated patients for 2-4 weeks and noticed a dramatic reduction in B-CLL cells in the blood. Treatment was continued for 8 - 12 weeks and an equally dramatic effect was noticed in the bone marrow, a major site of disease progression."

Further follow-up evaluation of the CAM 211 responders is ongoing.

In addition, the "Blood" article discussed positive preliminary results (an 83% response rate) of a study combining the treatment of Campath with Fludara. The data suggests that patients who have failed both single treatments can still benefit from a combination. The authors indicate that future large-scale trials should be undertaken.

[Warren Bluffet]

Übrigens:

Der Kurs in USA ist gestern nicht wie hier in W:o angezeigt mit 17,43 (+4,81%), sondern mit 17,90 (+7,64%) zu Ende gegangen.

D.h. in Euro 17,90/0,91 = 19,67 Euro

Gruß, Warren

http://finance.yahoo.com/q?s=ilxo&d=v1

[Warren Bluffet]

Hier die heutige Ad-hoc-Medlung dazu!!!

---------------------------------------------------------
ILEX Submits sBLA For CAMPATH In U.S.; Long-Term Efficacy and Safety Data Now Available

SAN ANTONIO, May 21, 2002 (BUSINESS WIRE) -- ILEX(TM) Oncology Inc. (Nasdaq:ILXO) announced today the filing of a supplemental biologics license application (sBLA) with the U.S. Food and Drug Administration (FDA) for CAMPATH(R) (alemtuzamab).
The request is based on long-term (two-year) follow-up data in patients who had been treated with alkylating agents and failed fludarabine. First-year results were recently published in the May 15, 2002 issue of Blood, Journal of the American Society of Hematology.

"Now that we have the final study data, we are committed to updating the CAMPATH label in order to provide community-based oncologists and hematologists with the most current data available," said Jeffrey H. Buchalter, President and CEO of ILEX.